March 9, 2020 / 11:48 AM / 21 days ago

BRIEF-Athenex Announces FDA Acceptance For Filing Of U.S. NDA For Tirbanibulin Ointment In Actinic Keratosis

March 9 (Reuters) - Athenex Inc:

* ATHENEX ANNOUNCES FDA ACCEPTANCE FOR FILING OF U.S. NDA FOR TIRBANIBULIN OINTMENT IN ACTINIC KERATOSIS

* ATHENEX -UNDER PDUFA ACT, FDA HAS SET TARGET ACTION DATE OF DEC 30, 2020 FOR TIRBANIBULIN OINTMENT

* ATHENEX- FDA HAS COMMUNICATED THAT IT IS NOT CURRENTLY PLANNING ON HOLDING AN ADVISORY COMMITTEE TO DISCUSS APPLICATION FOR TIRBANIBULIN OINTMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below